Previous studies reported that LCK is an oncogene and the use of LCK inhibitors can inhibit glioma growth, metastasis and the expression of cell stemness-related genes [37], and enhance cisplatin sensitivity in ovarian cancer [38]. This evidence concerns the gene LCK and ovarian carcinoma.